- Page 1 and 2:
Efficacy of pharmacological interve
- Page 3 and 4:
2.2.7 Clinical Course of IPF.......
- Page 5 and 6:
CHAPTER I: INTRODUCTION Idiopathic
- Page 7 and 8:
Progression-Free Survival (PFS) in
- Page 9 and 10:
is used (Azuma et al., 2005). The p
- Page 11 and 12:
Source: Adopted from Myllärniemi a
- Page 13 and 14:
disease is increased; however, no s
- Page 15 and 16:
CHAPTER II: LITERATURE REVIEW 2.1 I
- Page 17 and 18:
The dangerous disease basically att
- Page 19 and 20:
made between the inflammatory and f
- Page 21 and 22:
(Giotopoulos et al., 2007). RT of t
- Page 23 and 24:
derived cytokines, IL-5 and IL-9, m
- Page 25 and 26:
granulomatous lung disease, hence i
- Page 27 and 28:
infection and IPF (Wangoo et al., 1
- Page 29 and 30:
2.2.6 Pathophysiology Though the pa
- Page 31 and 32:
smoking (Rosas et al., 2007; Steele
- Page 33 and 34:
histological pattern of UIP in the
- Page 35 and 36:
The aim of this procedure is to rec
- Page 37 and 38:
procedures involving internal valid
- Page 39 and 40: adiological diagnosis of HRCT (Ragh
- Page 41 and 42: 2.2.11.1 Clinical Predictors Age: A
- Page 43 and 44: © 2017-2018 All Rights Reserved, N
- Page 45 and 46: studies and have exhibited that inc
- Page 47 and 48: Numerous physiologic parameters lik
- Page 49 and 50: Dense fibrosis and honeycombing is
- Page 51 and 52: Pharmacological treatment: Glucocor
- Page 53 and 54: i. Oxygen Therapy and ventilation I
- Page 55 and 56: Numerous patients with IPF acquirin
- Page 57 and 58: should be undergone to reveal wheth
- Page 59 and 60: CHAPTER III: RESEARCH METHODOLOGY T
- Page 61 and 62: 3.2 Meta-analysis of Randomised Con
- Page 63 and 64: 3.4.1 Inclusion criteria The inclus
- Page 65 and 66: 3.6.1 Dichotomous Comparisons The v
- Page 67 and 68: CHAPTER IV: RESULTS 4.1 Introductio
- Page 69 and 70: Following are the questions of the
- Page 71: Study number Table 2- CASP assessme
- Page 75: primary objective is to examined wh
- Page 79: to NAC inhaled inhaled NAC and oral
- Page 82: S. no Author; Year 1 Behr et al 7 C
- Page 86: pirfenidone combined with highdose
- Page 92 and 93: The general characteristics of the
- Page 95: for at least 8 weeks before randomi
- Page 99: © 2017-2018 All Rights Reserved, N
- Page 102 and 103: © 2017-2018 All Rights Reserved, N
- Page 105: 6 min walk the distinct possibility
- Page 109: percentage predicted FEV1, total lu
- Page 113: (DLco) of almost 43% of the predict
- Page 116 and 117: 4.7 Assessment of likelihood of com
- Page 118 and 119: espectively. However, one study by
- Page 120 and 121: the combined effects of these drugs
- Page 122 and 123: Pirfenidone, which is a proven ther
- Page 124 and 125: with respect to background factors
- Page 126 and 127: patient in the intervention group a
- Page 128 and 129: and N-acetylcysteine when combined
- Page 130 and 131: References Abehsera, M., Valeyre, D
- Page 132 and 133: from: http://www.ncbi.nlm.nih.gov/p
- Page 134 and 135: worsening of idiopathic pulmonary f
- Page 136 and 137: (6). pp. 515-20. Available from: ht
- Page 138 and 139: http://www.ncbi.nlm.nih.gov/pubmed/
- Page 140 and 141:
Hunninghake, G.W., Colby, T. V., Eg
- Page 142 and 143:
Diaz de Leon, A., Cronkhite, J.T.,
- Page 144 and 145:
predictors of a diagnosis of idiopa
- Page 146 and 147:
ole remains uncertain as anti-inter
- Page 148 and 149:
(2007). Occupational exposure and s
- Page 150 and 151:
Hillerdal, G., Nöu, E., Osterman,
- Page 152 and 153:
Increasing Global Mortality from Id
- Page 154 and 155:
pulmonary fibrosis. The New England
- Page 156 and 157:
Kim, D.S. (2006). Classification an
- Page 158 and 159:
from impaired collagen synthesis by
- Page 160 and 161:
and the American Society of Transpl
- Page 162 and 163:
Lung Foundation (2012). Idiopathic
- Page 164 and 165:
The Journal of urology. 114 (5). pp
- Page 166 and 167:
Circulating Fibrocytes Are an Indic
- Page 168 and 169:
nonspecific interstitial pneumonia/
- Page 170 and 171:
T.E., Lancaster, L., Sahn, S.A., Sz
- Page 172 and 173:
D.W. & Kitaichi, M. (2000). Increas
- Page 174 and 175:
Raghu, G., Brown, K.K., Bradford, W
- Page 176 and 177:
http://www.ncbi.nlm.nih.gov/pubmed/
- Page 178 and 179:
Bini, L. & Pallini, V. (2005). Cyto
- Page 180 and 181:
leomycin-induced lung damage in rat
- Page 182 and 183:
http://www.ncbi.nlm.nih.gov/pubmed/
- Page 184 and 185:
http://jcm.asm.org/cgi/doi/10.1128/
- Page 186 and 187:
Available from: http://www.ncbi.nlm
- Page 188 and 189:
Wells, A. (2015). Combination thera
- Page 190 and 191:
Shealy, D., Griswold, D.E. & Li, L.
- Page 192:
Zisman, D.A., Karlamangla, A.S., Ro